Epidermal growth factor receptor changes during breast cancer metastasis. 2006

Ilka B Fuchs, and Ildiko Siemer, and Helmut Bühler, and Annette Schmider, and Wolfgang Henrich, and Werner Lichtenegger, and Gerhard Schaller, and Sherko Kuemmel
Department of Gynecology, Charité C. Virchow, 13353 Berlin, Germany. ilka.fuchs@charite.de

BACKGROUND Since the anti-HER2 monoclonal antibody trastuzumab made its triumphant advance into breast cancer therapy, new selective agents, including pan-HER inhibitors are entering clinical practice. METHODS This study investigates the expression of the four HER-family members, HER1-4, in 48 primary breast carcinomas (PBC) and corresponding distant metastases (CDM) by immunohistochemistry and fluorescence in situ hybridisation. RESULTS Concordance rate between PBC and CDM was 79% for HERI and HER2, 67% for HER3 and 56% or HER4. Expression of HER1-3 was associated with poor prognosis compared to HER-negative disease (p = 0.036). HER4 overexpression was associated with a better outcome (p = 0.003). CONCLUSIONS Though most tumours demonstrate a stable HER expression pattern, both loss and acquisition of HER receptor overexpression can occur during metastasis. HER4 overexpression predicts prolonged survival compared to receptor negative disease, while the opposite is true for HER1-3. Consequences for modem antibody therapy are discussed.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D017404 In Situ Hybridization, Fluorescence A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei. FISH Technique,Fluorescent in Situ Hybridization,Hybridization in Situ, Fluorescence,FISH Technic,Hybridization in Situ, Fluorescent,In Situ Hybridization, Fluorescent,FISH Technics,FISH Techniques,Technic, FISH,Technics, FISH,Technique, FISH,Techniques, FISH
D066246 ErbB Receptors A family of structurally related cell-surface receptors that signal through an intrinsic PROTEIN-TYROSINE KINASE. The receptors are activated upon binding of specific ligands which include EPIDERMAL GROWTH FACTORS, and NEUREGULINS. EGF Receptor,Epidermal Growth Factor Receptor,Epidermal Growth Factor Receptor Family Protein,Epidermal Growth Factor Receptor Protein-Tyrosine Kinase,ErbB Receptor,HER Family Receptor,Receptor, EGF,Receptor, Epidermal Growth Factor,Receptor, TGF-alpha,Receptor, Transforming-Growth Factor alpha,Receptor, Urogastrone,Receptors, Epidermal Growth Factor-Urogastrone,TGF-alpha Receptor,Transforming Growth Factor alpha Receptor,Urogastrone Receptor,c-erbB-1 Protein,erbB-1 Proto-Oncogene Protein,EGF Receptors,Epidermal Growth Factor Receptor Family Proteins,Epidermal Growth Factor Receptor Kinase,HER Family Receptors,Proto-oncogene c-ErbB-1 Protein,Receptor Tyrosine-protein Kinase erbB-1,Receptor, ErbB-1,Receptors, Epidermal Growth Factor,Epidermal Growth Factor Receptor Protein Tyrosine Kinase,ErbB-1 Receptor,Family Receptor, HER,Family Receptors, HER,Proto oncogene c ErbB 1 Protein,Proto-Oncogene Protein, erbB-1,Receptor Tyrosine protein Kinase erbB 1,Receptor, ErbB,Receptor, ErbB 1,Receptor, HER Family,Receptor, TGF alpha,Receptor, Transforming Growth Factor alpha,Receptors, EGF,Receptors, Epidermal Growth Factor Urogastrone,Receptors, ErbB,Receptors, HER Family,c erbB 1 Protein,c-ErbB-1 Protein, Proto-oncogene,erbB 1 Proto Oncogene Protein

Related Publications

Ilka B Fuchs, and Ildiko Siemer, and Helmut Bühler, and Annette Schmider, and Wolfgang Henrich, and Werner Lichtenegger, and Gerhard Schaller, and Sherko Kuemmel
September 1988, Gan to kagaku ryoho. Cancer & chemotherapy,
Ilka B Fuchs, and Ildiko Siemer, and Helmut Bühler, and Annette Schmider, and Wolfgang Henrich, and Werner Lichtenegger, and Gerhard Schaller, and Sherko Kuemmel
January 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
Ilka B Fuchs, and Ildiko Siemer, and Helmut Bühler, and Annette Schmider, and Wolfgang Henrich, and Werner Lichtenegger, and Gerhard Schaller, and Sherko Kuemmel
April 1997, Journal of mammary gland biology and neoplasia,
Ilka B Fuchs, and Ildiko Siemer, and Helmut Bühler, and Annette Schmider, and Wolfgang Henrich, and Werner Lichtenegger, and Gerhard Schaller, and Sherko Kuemmel
November 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Ilka B Fuchs, and Ildiko Siemer, and Helmut Bühler, and Annette Schmider, and Wolfgang Henrich, and Werner Lichtenegger, and Gerhard Schaller, and Sherko Kuemmel
February 2002, Archives of pathology & laboratory medicine,
Ilka B Fuchs, and Ildiko Siemer, and Helmut Bühler, and Annette Schmider, and Wolfgang Henrich, and Werner Lichtenegger, and Gerhard Schaller, and Sherko Kuemmel
August 1990, Biochemical Society transactions,
Ilka B Fuchs, and Ildiko Siemer, and Helmut Bühler, and Annette Schmider, and Wolfgang Henrich, and Werner Lichtenegger, and Gerhard Schaller, and Sherko Kuemmel
November 2012, Breast cancer research and treatment,
Ilka B Fuchs, and Ildiko Siemer, and Helmut Bühler, and Annette Schmider, and Wolfgang Henrich, and Werner Lichtenegger, and Gerhard Schaller, and Sherko Kuemmel
September 2008, OncoTargets and therapy,
Ilka B Fuchs, and Ildiko Siemer, and Helmut Bühler, and Annette Schmider, and Wolfgang Henrich, and Werner Lichtenegger, and Gerhard Schaller, and Sherko Kuemmel
November 2012, Cancer,
Ilka B Fuchs, and Ildiko Siemer, and Helmut Bühler, and Annette Schmider, and Wolfgang Henrich, and Werner Lichtenegger, and Gerhard Schaller, and Sherko Kuemmel
November 2011, Lung cancer (Amsterdam, Netherlands),
Copied contents to your clipboard!